Komori
Share Issuance and Disposal4893Noile-Immune Biotech Inc.Pharmaceuticals

Supplementary Information on Financing through the Issuance of Stock Acquisition Rights

Materials were released explaining the purpose of the financing, use of funds, issuance terms and business strategy concerning the issuance of Series 14 Warrants through a private placement. The materials do not amend existing disclosures.

Worth reading
—
Scored from 0 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1349
¥ millions (planned proceeds and estimated net proceeds)
Wording
Avoiding a definitive answer
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-09-18
What was corrected and how
ItemDetails
Items this document does not state (6)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correctionImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

These materials were prepared to provide information on the issuance of Series 14 Warrants through a private placement. The stated purpose of the financing is to secure additional growth investment funds to enhance the value and competitiveness of existing CAR-T and promote in vivo CAR-T as a new growth opportunity.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Information on Financing through the Issuance of Stock Acquisition Rights | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori